June 30, 2013
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced interim results from a proof of concept Phase 1/2 clinical trial evaluating the activity and local tolerability of HTI-501, an investigational biologic, for use in aesthetic dermatology. The data were presented
June 29, 2013
at the 9
Annual World Congress of Cosmetic Dermatology in
This trial is being conducted outside the US in healthy adult females with cellulite, known medically as edematous fibrosclerotic panniculopathy. The Phase 1 dose-escalation portion of the trial was completed in 2012 while the ongoing Phase 2 portion of the trial is designed to assess the pharmacologic activity of HTI-501 and extend the safety assessment to multiple injections in a treatment area. The primary endpoint is physician assessment at Day 28, supported by secondary endpoints of subject self-evaluations and objective measurements of changes to the skin topography.
The interim results from 12 of the planned 34 evaluable patients from this Phase 1/2 trial indicates pharmacologic activity at the primary 28 day observation point, with 83 percent of subjects (10 of 12) showing improvement from the pretreatment assessment, with a median improvement of 53 percent (p=.006) by the primary physician assessment. In comparison, 75 percent of subjects (9 of 12) showed improvement with a median improvement of 22 percent (p=.009) for the vehicle injection control at the same observation point. The objective measure (skin topography) for the treated area showed modest improvement in 80 percent of evaluable subjects (8 of 10) treated with HTI-501 (p=.042), but was not significantly changed for the vehicle control (p=.84) or a post-hoc evaluation of non-injected areas. To query the robustness of any study conclusions, an independent blinded panel evaluation of images will be performed on the evaluable subjects at one and six months following treatment.